Hi,This is an article from May last, sorry I thought it was...

Hi,

This is an article from May last, sorry I thought it was later so I don't think there is anything to worry about there.... as for the other poster knowing something we don't I'd be surprised and I'm not worried at all. ACR is an amazing success story and the expectation of more products being released is always a point of discussion re approvals/timing/partnerships etc

cheers


21 May 2010
Australian Financial Review

Sigma Pharmaceuticals? chairman John Stocker (director of Telstra, Nufarm and CSIRO) announced his retirement from the board yesterday, which has further dwarfed the debt-ridden drug maker as it faces the tough task of offloading $100 million worth of assets to avoid another breach of its debt covenants. Furthermore, it will be hit by the federal government?s plan to cut $2.5 billion from the cost of generic drugs over five years; and will be affected by the government?s $1.9 billion agreement with Medicines Australia.

Mr Stocker?s successor is Sigma director and ex-KPMG partner Brian Jamieson, who is on the board of Tatts Group and Oz Minerals. Sigma is also short of a chief executive; Richard Treagus (chief executive at Acrux) is said to be in the running for the job, while PaperlinX chief financial officer has been named as a possible candidate for the role.